40 results about "Maturation inhibitor" patented technology

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-28 amines of C-3 modified betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS. In particular, the following compounds are provided herein, including pharmaceutically acceptable salts thereof:a compound of formula Ia compound of formula IIand a compound of formula III

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 betulinic acid and other structurally related natural products derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 and C-28 betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I:with X selected from C4-8 cycloalkyl, C4-8 cycloalkenyl, C4-9 spirocycloalkyl, C4-9 spirocycloalkenyl, C4-8 oxacycloalkyl, C4-8 dioxacycloalkyl, C6-8 oxacycloalkenyl, C6-8 dioxacycloalkenyl, C6 cyclodialkenyl, C6 oxacyclodialkenyl, C6-9 oxaspirocycloalkyl and C6-9 oxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is —C1-6 alkyl-halo. These compounds are useful for the treatment of HIV and AIDS.

Compounds of Formula I:that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.

Compounds of Formula I:that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I:These compounds are useful for the treatment of HIV and AIDS.

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 bicyclic amines of triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III:These compounds are useful for the treatment of HIV and AIDS.

Co-formulations of HIV maturation inhibitor compound with one or two other HIV compounds, and methods of treatment, are set forth.

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I:These compounds are useful for the treatment of HIV and AIDS.

The invention discloses the use of hsa-miRNA-423-5p in the preparation of an autophagy maturation inhibitor, and the use of the hsa-miRNA-423-5p inhibitor in the preparation of a drug for treating tuberculosis. The expression level of hsa-miRNA-423-5p provided by the present invention in the serum of tuberculosis patients is significantly higher than that of healthy controls, and it is confirmed that when hsa-miRNA-423-5p is highly expressed, it can lead to obvious autophagy maturation blocking phenomenon; hsa When the expression of ‑miRNA‑423‑5p is inhibited, the phenomenon of autophagy maturation inhibition is relieved. Therefore, hsa‑miRNA‑423‑5p can be used as a good target for the treatment of tuberculosis. Moreover, hsa-miRNA-423-5p is a small molecule that exists by itself, so it is superior to chemical drugs in terms of side effects, and will not cause drug-resistant tuberculosis due to repeated medication.